Norway – Medical equipments, pharmaceuticals and personal care products – 2799a HAE

Opportunity description

The contracting authority for this competition is Sykehusinnkjøp HF, on behalf of the four regional health authorities in Norway: Helse Sør-Øst RHF, Helse Vest RHF, Helse Midt-Norway RHF and Helse Nord RHF. The contracting authority shall, on behalf of the four regional health authorities (RHF), procure a new procurement within hereditary angioedema (HAE) disease. The contracting authority for this competition is Sykehusinnkjøp HF, on behalf of the four regional health authorities in Norway: Helse Sør-Øst RHF, Helse Vest RHF, Helse Midt-Norway RHF and Helse Nord RHF. The contracting authority shall, on behalf of the four regional health authorities in Norway enter into framework agreements for the procurement of medicines with active ingredient for heriditarian angioedema (HAE) disease. The procurement includes the following ATC groups: B06AC01 - C1 inhibitor B06AC02 - Ikatibant B06AC04 - Konestat alfa B06AC05 - Lanadelumab B06AC06 - Beroltral state B06AC07 - Garadacimab B06AC08 - Sebetral state B06AC09 - Donidalorsen See Annex 3 Requirement Specifications and The Competition Provisions for detailed information. Procedure: open. Review the original TED notice for the complete requirement, lots, amendments and attachments.